Tyra Biosciences, Inc. - Margin dodolan resik TYRA

Tandha merek tyra.bio (TYRA)

Tyra Biosciences, Inc. (TYRA) maintains strong pricing power based on the development of selective AI-driven FGFR inhibitors. The net profit margin reflects efficiency dynamics, where the current status is 0.00. Growth potential is driven by sales of drugs for the treatment of lung and bladder cancers. A flawless reputation in precision oncology guarantees the company steady support from major investors.

tyra.bio (TYRA) - Rentabilitas dodolan resik saka 04.07.2022 nganti 20.11.2026

Tyra Bio - rincian analitis lan metrik utama (TYRA)

- rega saham lan konsensus proyeksi valuasi:
Ringkesan analitik perusahaan:Tyra Corp - TYRA
Produk dadi Tyra Biosciences Inc

The absence of commercial revenue coupled with intensive R&D expenditures for the SNAPR platform results in negative net profit margins for Tyra Biosciences, Inc. (TYRA). This indicator, calculated as the ratio of net income to revenue, measures the efficiency of monetizing each unit of sales, which under current conditions highlights Tyra Biosciences, Inc. (TYRA)'s heavy reliance on external financing and the risks of a high cash burn rate.